louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02194140: Improvement of Appendix Identification and Appendicitis Diagnosis in us After Administration of Oral Contrast Medium
Official title: Improvement of Appendix Identification and Appendicitis Diagnosis in Ultrasound After Administration of Iodinated Oral Contrast Medium
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Appendicitis
Keywords: ultrasound
iodinated contrast material
computed tomography
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2014-07-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Rate of appendix localization on ultrasound is not high. We suggest a way to improve it's localization by oral administration of iodinated contrast material.

Detailed description: The administration of oral iodinated contrast material might facilitate identification of the appendix and accurate diagnosis of appendicitis. When indicated will shorten time to CT examination.

Eligibility criteria: Inclusion Criteria:

* patients in emergency department with right lower quadrant pain

Exclusion Criteria:

* patients under 18 years old
* pregnant women

Primary outcomes:
measure: Appendix identification rate on ultrasound
timeFrame: At the time of ultrasound examination up to 1 hour
Secondary outcomes:
measure: improved rate of correctly diagnosed appendicitis
timeFrame: At time of surgery or patholoy results if available within 14 days
Other outcomes:
measure: shortening waiting time for CT
timeFrame: At time of CT examination up to 1 hour
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center Hadera Israel
name: Nadir Reindorp, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Trout AT, Sanchez R, Ladino-Torres MF, Pai DR, Strouse PJ. A critical evaluation of US for the diagnosis of pediatric acute appendicitis in a real-life setting: how can we improve the diagnostic value of sonography? Pediatr Radiol. 2012 Jul;42(7):813-23. doi: 10.1007/s00247-012-2358-6. Epub 2012 Mar 9.
Clinical trial NCT04246840: Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
Official title: Study Through Imaging of Mediastinal and Abdominopelvic Secondary Lymphoid Organs (Lymph Nodes) in Patients With Severe Combined Immunodeficiencies (SCID) Who Have Recieved Bone Narrow Allograft
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Severe Combined Immunodeficiency
Lead sponsor: Association Pour l'Aide a la Recherche en Immunologie Pediatrique
Sponsor class: OTHER
First posted: 2020-01-29
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with SCID transplanted 15-45 years ago and healthy conrtrols

Brief summary: To investigate the presence of seconday of lymphoid organs in patients who underwent allogenic hematopoietic stem cell transplantation 15 to 45 years ago.

The goal aims to assess the development of seconday lymphoid organs given the fact that the absence of myeloablation these patients present a split chimerism between T lymphocytes and the other leucocytes. Thus, they may not be able to generate seconday lymphoid organs. Practically, whole body MRI is being used to visualise and quantify both mediastinal and intraabdominal lymph nodes. Delta will be compared with those obtained in healthy age-matched individuals. It is scheduled to include 15 patients and 15 controls.


Eligibility criteria: Inclusion Criteria:

* Patients with SCID transplanted 15-45 years ago

Exclusion Criteria:

* None

Primary outcomes:
measure: Size of mediastinal and intraabdominal lymph nodes
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Necker
Study officials:
References:
citation: Berteloot L, Molina TJ, Bruneau J, Picard C, Barlogis V, Secq V, Abdo C, Boddaert N, Griscelli C, Neven B, Fischer A. Alternative pathways for the development of lymphoid structures in humans. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2108082118. doi: 10.1073/pnas.2108082118.
Clinical trial NCT02632240: Collagen Matrix With Tunnel Technique Compared to CTG for the Treatment of Periodontal Recessions
Official title: Collagen Matrix With Tunnel Technique Compared to CTG for the Treatment of Periodontal Recessions - Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingival Recession
Keywords: gingival recession
mucogingival surgery
collagen matrix
connective tissue graft
tunnel technique
Lead sponsor: Medical University of Silesia
Sponsor class: OTHER
First posted: 2015-12-16
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the efficacy of dental root coverage using the tunnel technique with connective tissue graft (CTG) and the same technique with collagen matrix for treatment of multiple gingival recessions Miller Class I and II.

This study is a randomized-controlled clinical trial of 6 months duration.

Detailed description: According to the medical databases, there are limited randomized clinical trials comparing xenogenic collagen matrix and CTG used with the tunnel technique. The collagen matrix is a possible alternative to connective tissue graft.

The purpose of this clinical study is to compare short-term (3-6 months) outcomes of a root coverage using the tunnel technique with the collagen matrix and the same technique with CTG for the treatment of multiple recessions Miller class I and II.

Twenty eight patients are enrolled in the study. Patients in the test group are treated with xenogenic collagen matrix using the tunnel technique whereas patients in the control group with CTG. Clinical recordings are obtained at baseline and after 3 and 6 months. The percentage of average recession coverage (ARC) is evaluated after 3 and 6 months after the surgery.

Eligibility criteria: Inclusion Criteria:

* Presence of minimum two adjacent periodontal recessions Miller class I or II and at least 2 mm recessions depth.

Exclusion Criteria:

* Approximal Plaque Index (API) \> 15%,
* Sulcus Bleeding Index (SBI) \> 10%,
* Systemic diseases with compromised healing potential or infectious diseases,
* Untreated periodontal conditions,
* Pregnant and lactating females.

Primary outcomes:
measure: Clinical attachment level (CAL)
timeFrame: 6 months
Secondary outcomes:
measure: Recession depth (RD)
timeFrame: 6 months
measure: Recession width (RW)
timeFrame: 6 months
measure: Width of keratinized tissue (KTW)
timeFrame: 6 months
measure: Recession area (RA)
timeFrame: 6 months
measure: the average percentage of root coverage (ARC)
timeFrame: 6 months
measure: The complete coverage of recessions (CRC)
timeFrame: 6 months
Other outcomes:
measure: The depth of gingival sulcus (PD)
timeFrame: 6 months
Locations:
city: Zabrze
country: Poland
facility: Department of Periodontal and Oral Mucosa Diseases
Study officials:
affiliation: Department of Conservative Dentistry with Endodontics
name: Marta Tanasiewicz, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT06668740: Evaluation of a Program to Improve the Life Quality of Elderly
Official title: The Influence of Using Virtual Reality Glasses on the Quality of Life of the Elderly
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Elderly
Keywords: VirtualReality
Quality of Life
Elderly
Lead sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 22
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Older people belong to an age group that has been increasing in recent decades, leading to a progressive ageing of the population. With the aim of reducing the generational digital divide, the use of technology in retirement homes was proposed. To this end, virtual reality glasses were used to allow the visualization of an external virtual world and, subsequently, it was evaluated whether their application improved the quality of life of the elderly by reducing the difficulties they have in participating in recreational activities outside these centers. A prospective quasi-experimental longitudinal study was carried out in the centers belonging to the basic health area of Valls, with a study period from May 2023 to March 2024. Quality of life was measured using the ad hoc "Escala de Calidad de Vida Rivas-Bordas".


Eligibility criteria: Inclusion Criteria:

* Age 65 or older.
* Resident of a geriatric home in the Valls area.
* Individuals with slight, moderate, fair, or total impairment of social resources, as assessed by the Duke University Center (1978) Social Resources Scale (OARS).

Exclusion Criteria:

* Individuals with a history of frequent migraines or motion sickness.
* Individuals with moderate or severe cognitive impairment (≥ 5 errors on the Abbreviated Pfeiffer test).
* Inability to communicate in Spanish and/or Catalan.
* Individuals with advanced visual and/or hearing impairments.

Primary outcomes:
measure: Level of Quality of Life
timeFrame: pre-intervention and immediately after post-intervention
Secondary outcomes:
measure: Gender
timeFrame: pre-intervention
measure: Marital Statuts
timeFrame: pre-intervention
Other outcomes:
Locations:
city: Bellcaire d'Urgell
country: Spain
facility: Delia Borda Fortuny
state: Lleida
Study officials:
References:
Clinical trial NCT06374940: Surgical Outcomes of Conventional Hysterectomy or Manipulator-assisted Abdominal Hysterectomy
Official title: The Comparison of Surgical Outcomes to Conventional Hysterectomy and Manipulator-assisted Abdominal Hysterectomy
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Gynecologic Disease
Keywords: Hysterectomy, Manipulator-assisted abdominal hysterectomy
Lead sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2024-04-19
Enrollment: 140
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Objective: The comparison of surgical outcomes conventional hysterectomy and manipulator-assisted hysterectomy

Study design: Prospective randomized controlled trial. Allocation to either group occurred via computer-generated random numbers. Sequentially numbered, opaque envelopes were prepared according to randomization. The patients were unaware of whether they would undergo a conventional hysterectomy or manipulator-assisted abdominal hysterectomy for their surgical procedure. The research coordinator unveiled group assignments upon individual patient recruitment by opening the corresponding envelope.

Study population: Inclusion criteria were patients aged 40-70 years who underwent hysterectomy for benign gynecological indications.

Primary outcomes: (1) Operation Time.

Secondary outcomes: (1) Postoperative early pain (Visual Analog Score (VAS) at 6th and 24th hours of the surgery) (2) intraoperative complications, (3) postoperative complications


Eligibility criteria: Inclusion Criteria:

* Inclusion criteria were patients aged 40-70 years who underwent hysterectomy for benign gynecological indications

Exclusion Criteria:

* Exclusion criteria were patients with additional procedures such as urogynecologic procedures, history of abdominal surgery with midline incision, patients with suspected gynecologic malignancy, endometriosis, tubo-ovarian abscess, pelvic organ prolapse, or those who refused to participate in the study and whose medical records could not be obtained.

Primary outcomes:
measure: Duration of the surgical procedure
timeFrame: intraoperative
Secondary outcomes:
measure: Postoperative pain at 6th hours
timeFrame: At the 6th hours after the surgical procedure
measure: Postoperative pain at 24th hours
timeFrame: At the 24th hours after the surgical procedure
measure: intraoperative complications
timeFrame: Intraoperative
measure: Postoperative complications
timeFrame: Postoperative, in the first month of the surgery
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Dr.Lütfi Kırdar City Hospital
Study officials:
References:
Clinical trial NCT06686940: Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden
Official title: Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atrial Fibrillation (AF)
Keywords: atrial fibrillation burden
Photoplethysmography
Wearable devices.
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2024-11-13
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with atrial fibrillation who meet age and health criteria can use electrocardiographic watches for long-term monitoring.

Brief summary: The purpose of this study is to evaluate the monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.


Eligibility criteria: Inclusion Criteria:

1. Atrial fibrillation patients diagnosed by electrocardiogram
2. Willing to use long-range electrocardiogram monitoring equipment

Exclusion Criteria:

1.Patients who are allergic to electronic devices or unable to wear watches

Primary outcomes:
measure: Primary outcome
timeFrame: December 30, 2024 to Decemberr 30, 2034
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT02993640: Optimization of Hepatic Hemodynamics During Liver Surgery
Official title: Effects of Vasopressin and Nitroglycerine in Combination on Splanchnic Blood Flow, and on Hepatic and Portal Venous Pressures in Liver Resection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Portal Blood Pressure
Liver Surgery
Hepatic Hemodynamics
Keywords: vasopressin
nitroglycerine
portal pressure
portal flow
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
First posted: 2016-12-15
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine if vasopressin and nitroglycerin in combination will affect hepatic hemodynamics, in the setting of liver surgery.

Detailed description: The patients in this study (undergoing elective liver resection) will be anesthetized according to routine practice in our hospital. A radial arterial catheter and a central venous catheter will be inserted, as well as a femoral arterial catheter for Picco monitoring. After the dissection phase, catheters will be inserted in the portal and hepatic veins by the surgeon. Base line data (HR, CVP, MAP, CO from thermodilution, portal and hepatic venous pressure, blood gases from radial artery, vena cava superior, hepatic vein and portal vein) will be obtained twice, with 10 minutes of steady state in between. An infusion of vasopressin 4,8 U/h will then be started and continued for 20 minutes. Data will be collected again, and an infusion of nitroglycerine (to a target of MAP 60 mmHg) will be added. After 5 minutes of steady MAP 55-65, the last set of data is collected. 12 Patients will be recruited, and the total data collection is estimated to be completed and assessed after six to nine months.

Eligibility criteria: Inclusion Criteria:

* Patients within ASA-class I-II scheduled for open liver resection

Exclusion Criteria:

* ASA-class III and IV, more than 2 medications for hypertension, BMI \> 35, technical difficulties with insertion av catheters, extensive surgery.

Primary outcomes:
measure: Portal and hepatic venous flow after vasopressin and nitroglycerine infusion
timeFrame: six - nine months
measure: Pressure in the hepatic and portal veins after vasopressin and nitrovasopressin infusion
timeFrame: six - nine months
Secondary outcomes:
measure: lactate in the splanchnic circulation
timeFrame: six-nine months
Other outcomes:
Locations:
Study officials:
affiliation: Sahlgrenska University Hospital
name: Sven-Erik Ricksten, Professor
role: STUDY_DIRECTOR
References:
citation: Wisen E, Svennerholm K, Bown LS, Houltz E, Rizell M, Lundin S, Ricksten SE. Vasopressin and nitroglycerin decrease portal and hepatic venous pressure and hepato-splanchnic blood flow. Acta Anaesthesiol Scand. 2018 Aug;62(7):953-961. doi: 10.1111/aas.13117. Epub 2018 Mar 26.
Clinical trial NCT04415801: Effect of Repeated Removal and Re-placement of Abutments Around Dental Implants
Official title: Effect of Repeated Removal and Re-placement of Laser Microgrooved and Machined Abutments on Proinflammatory Cytokine Levels Around Dental Implants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Peri-implant Mucositis
Keywords: Peri-implant Mucositis
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2020-06-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: Repeated removal and re-placement of healing and prosthetic abutments result in frequent injuries to the soft tissues. The purpose was to evaluate the effect of repeated removal and re-placement of laser microgrooved and smooth/machined healing and prosthetic abutments during restorative stages, and 1 year after functional loading, on proinflammatory cytokine levels around dental implants.

Detailed description: Twenty-four patients each received 2 one-stage implants in a split mouth design on the same jaw. In each patient one healing and prosthetic abutments with a laser microgrooved surface (LMS group) and one healing and prosthetic abutments with smooth/machined surface (S/MS group) were used. Four months following implant placement \[Baseline (BSL)\], the healing abutments were disconnnected and reconnected three times to carry out the impression procedures and metal framework try-in. Four weeks later (T0), definitive prosthetic abutments were installated with screw retained crowns. Samples for immunological analyses were taken from the sulcus around each implant at BSL, T0, and 1 year after functional loading (T1). Peri-implant crevicular fluid samples were analyzed for interleukin-1beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α levels using the ELISA kit.

Eligibility criteria: Inclusion Criteria:

* 18 years or older, in good general health, and with sufficient amount of bone available to place a standard implant

Exclusion Criteria:

* natural teeth adjacent to surgical area affected by untreated periodontal or endodontic infections, peri-implant bone defects requiring bone augmentation, absence of opposing occlusion,

Primary outcomes:
measure: change from baseline to 8 weeks of gingival fluid production
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Universita la Sapienza
Study officials:
affiliation: University La Sapienza Roma Italy
name: Renzo Guarnieri
role: PRINCIPAL_INVESTIGATOR
References:
citation: Guarnieri R, Miccoli G, Reda R, Mazzoni A, Di Nardo D, Testarelli L. Laser microgrooved vs. machined healing abutment disconnection/reconnection: a comparative clinical, radiographical and biochemical study with split-mouth design. Int J Implant Dent. 2021 Mar 17;7(1):19. doi: 10.1186/s40729-021-00301-6.
Clinical trial NCT02694601: Ketone Production With Acute Caffeine Intake
Official title: Stimulate the Ketogenesis by Using a Caffeine Supplement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Adults
Keywords: Ketones
Glucose
Caffeine
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
First posted: 2016-02-29
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10).

Detailed description: The aim of the study is to evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10). Two different doses of caffeine (2.5 mg/kg of BW and 5 mg/kg of BW) are compared. All the participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.

Eligibility criteria: Inclusion Criteria:

* Healthy adults
* 18 years old and over

Exclusion Criteria:

* Drinking more than 300 mg of caffeine per day
* Diabetes or prediabetes
* Abnormal liver and kidney function
* Uncontrolled dyslipidemia, blood pressure
* Use of drugs known to influence the metabolism of lipids and carbohydrates (steroid, beta-blockers, diuretics, insulin sensitizer, etc.)
* Severe inflammation or infection
* Pregnancy
* Smoking

Primary outcomes:
measure: Plasma Acetoacetate Concentrations
timeFrame: 4 hours
measure: Plasma Beta-hydroxybutyrate Concentrations
timeFrame: 4 hours
Secondary outcomes:
measure: Plasma Glucose Concentrations
timeFrame: 4 hours
measure: Plasma Cholesterol Concentrations
timeFrame: 4 hours
measure: Plasma Triglyceride Concentrations
timeFrame: 4 hours
Other outcomes:
Locations:
city: Sherbrooke
country: Canada
facility: Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)
state: Quebec
Study officials:
affiliation: Research Centre on Aging - CSSS-IUGS - CIUSSS de l'Estrie - CHUS
name: Stephen Cunnane, PhD
role: PRINCIPAL_INVESTIGATOR
References: